104 related articles for article (PubMed ID: 9049182)
1. Upregulation of endogenous p53 and induction of in vivo apoptosis in B-lineage lymphomas of E(mu)-myc transgenic mice by deregulated c-myc transgene.
Prasad VS; LaFond RE; Zhou M; Jacobsen KA; Osmond DG; Sidman CL
Mol Carcinog; 1997 Feb; 18(2):66-77. PubMed ID: 9049182
[TBL] [Abstract][Full Text] [Related]
2. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
Eischen CM; Weber JD; Roussel MF; Sherr CJ; Cleveland JL
Genes Dev; 1999 Oct; 13(20):2658-69. PubMed ID: 10541552
[TBL] [Abstract][Full Text] [Related]
3. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
[TBL] [Abstract][Full Text] [Related]
4. Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV.
Zörnig M; Grzeschiczek A; Kowalski MB; Hartmann KU; Möröy T
Oncogene; 1995 Jun; 10(12):2397-401. PubMed ID: 7784089
[TBL] [Abstract][Full Text] [Related]
5. Survival and death of prelymphomatous B-cells from N-myc/bcl-2 double transgenic mice correlates with the regulation of intracellular Ca2+ fluxes.
Zörnig M; Busch G; Beneke R; Gulbins E; Lang F; Ma A; Korsmeyer S; Möröy T
Oncogene; 1995 Nov; 11(10):2165-74. PubMed ID: 7478538
[TBL] [Abstract][Full Text] [Related]
6. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Ras, Raf and L-myc but not Bcl-2 family proteins is linked with resistance to TCR-mediated apoptosis and tumorigenesis in thymic lymphomas from TCR transgenic mice.
Kobzdej M; Matuszyk J; Strzadala L
Leuk Res; 2000 Jan; 24(1):33-8. PubMed ID: 10634643
[TBL] [Abstract][Full Text] [Related]
8. E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice.
Möröy T; Verbeek S; Ma A; Achacoso P; Berns A; Alt F
Oncogene; 1991 Nov; 6(11):1941-8. PubMed ID: 1658705
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis and macrophage-mediated deletion of precursor B cells in the bone marrow of E mu-myc transgenic mice.
Jacobsen KA; Prasad VS; Sidman CL; Osmond DG
Blood; 1994 Oct; 84(8):2784-94. PubMed ID: 7522642
[TBL] [Abstract][Full Text] [Related]
10. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis.
Alt JR; Greiner TC; Cleveland JL; Eischen CM
EMBO J; 2003 Mar; 22(6):1442-50. PubMed ID: 12628936
[TBL] [Abstract][Full Text] [Related]
11. bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis.
Haupt Y; Bath ML; Harris AW; Adams JM
Oncogene; 1993 Nov; 8(11):3161-4. PubMed ID: 8414519
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of B-lymphoid tumors in E mu-myc transgenic mice.
Prasad VS; Temple MJ; Davisson MT; Akeson EC; Sidman CL
Cytometry; 1996 Feb; 23(2):131-9. PubMed ID: 8742172
[TBL] [Abstract][Full Text] [Related]
13. MHC class I expression on prelymphomatous and lymphomatous B-cells is not inhibited by an E mu-myc transgene.
Algarra I; Silva S; Ljunggren HG
Eur J Cancer; 1993; 29A(2):238-41. PubMed ID: 8422288
[TBL] [Abstract][Full Text] [Related]
14. The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice.
Elson A; Deng C; Campos-Torres J; Donehower LA; Leder P
Oncogene; 1995 Jul; 11(1):181-90. PubMed ID: 7624126
[TBL] [Abstract][Full Text] [Related]
15. C-myc-induced apoptosis in polycystic kidney disease is Bcl-2 and p53 independent.
Trudel M; Lanoix J; Barisoni L; Blouin MJ; Desforges M; L'Italien C; D'Agati V
J Exp Med; 1997 Dec; 186(11):1873-84. PubMed ID: 9382886
[TBL] [Abstract][Full Text] [Related]
16. A p53 defect sensitizes various stages of B cell development to lymphomagenesis in mice carrying an IgH 3' regulatory region-driven c-myc transgene.
Fiancette R; Rouaud P; Vincent-Fabert C; Laffleur B; Magnone V; Cogné M; Denizot Y
J Immunol; 2011 Dec; 187(11):5772-82. PubMed ID: 22039300
[TBL] [Abstract][Full Text] [Related]
17. Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors.
Sheppard RD; Samant SA; Rosenberg M; Silver LM; Cole MD
Oncogene; 1998 Oct; 17(16):2073-85. PubMed ID: 9798678
[TBL] [Abstract][Full Text] [Related]
18. Allele-specific loss or imbalance of chromosomes 9, 15, and 16 in B-cell tumors from interspecific F1 hybrid mice carrying Emu-c-myc or N-myc transgenes.
Linardopoulos S; Silva S; Klein G; Balmain A
Int J Cancer; 2000 Dec; 88(6):920-7. PubMed ID: 11093815
[TBL] [Abstract][Full Text] [Related]
19. Cell death regulation during multistep lymphomagenesis.
Hsu B; Marin MC; McDonnell TJ
Cancer Lett; 1995 Jul; 94(1):17-23. PubMed ID: 7621440
[TBL] [Abstract][Full Text] [Related]
20. High frequency of myelomonocytic tumors in aging E mu L-myc transgenic mice.
Möröy T; Fisher PE; Lee G; Achacoso P; Wiener F; Alt FW
J Exp Med; 1992 Feb; 175(2):313-22. PubMed ID: 1310099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
